Posttransplantation: Emerging and future therapies

Seminars in Liver Disease

Volumn 20, Issue 1 SUPPL., 2000, Pages 13-17

  Perrillo, Robert P ^a   Kruger, Martin ^b   Sievers, Theodore ^c   Lake, John R ^d  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Famciclovir; Ganciclovir; Lamivudine; Therapy

Indexed keywords

ANTIVIRUS AGENT; FAMCICLOVIR; GANCICLOVIR; HEPATITIS B ANTIBODY; HUMAN IMMUNOGLOBULIN; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS DNA;

CONFERENCE PAPER; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; RECURRENCE RISK; REINFECTION; SURVIVAL RATE; VIRUS MUTATION; VIRUS REPLICATION;

2-AMINOPURINE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GANCICLOVIR; HEPATITIS B; HUMANS; LAMIVUDINE; LIVER TRANSPLANTATION; NUCLEOSIDES; POSTOPERATIVE CARE; RECURRENCE; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0033918262     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991;13:150-157
2. Todo S, DeMetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related disease. Hepatology 1991;13:619-626
3. Nakazono K, Ito Y, Wu CH, Wu GY. Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology 1996;23:1297-1303
4. Grellier L, Dusheiko GM. Hepatitis B virus and liver transplantation: Concepts in antiviral prophylaxis. J Viral Hepatol 1997;4(Suppl 1):111-116
5. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin Hepatology 1996;24:1327-1333
6. Tchervenkov JI, Tector AJ, Barkun JS, et al. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg 1997;226:356-365
7. Burbach GJ, Bienzel U, Neuhaus R, et al. Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation. Transplantation 1997;63:478-480
8. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61:1358-1364
9. Lowell JA, Burgess S, Shenoy S, et al. Mercury poisoning associated with high-dose hepatitis B immune globulin administered alter liver transplantation for chronic hepatitis B. Liver Transplant Surg 1996;2:475-478
10. Ghary MG, Ayola B, Villamil FG, et al. Hepatitis B virus mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998;27: 213-222
11. Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998;27:254-263
12. Hoofnagle JH, Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356
13. Terrault NA, Holland CC, Ferrell L, et al. Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transplant Surg 1996;2:132-138
14. Gish RG, Keefe EB, Lim J, et al. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. Hepatology 1995;22:257-262
15. Muller R, Gubernais G, Farle M, et al. Liver transplantation in HBs antigen (HbsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. Hepatology 1991;13:90-96
16. Nymann T, Shokouh-Amiri MH, Vera SR, et al. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation. Clin Transplant 1996;10:663-667
17. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212-1215
18. Perrillo R, Rakela J, Martin P, et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation (OLT) [abstract]. Hepatology 1997;26:260a
19. Markowitz JS, Martin P, Conrad AJ. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin [abstract]. Hepatology 1997;26:152a
20. Kruger M, Tillman HL, Trautwein C, et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study. Liver Transplant Surg 1996;2:253-262
21. Perrillo R, Rakela J, Martin P, et al. Long term lamivudine therapy of patients with recurrent hepatitis B post liver transplantation [abstract]. Hepatology 1997;26:177a
22. Gish RG, Lau JYN, Brooks L, et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996;23:1-7
23. Shields PL, Ling R, Harrison T, et al. Management and outcome of lamivudine (LAM) resistant hepatitis B virus (HBV) infection after liver transplantation [abstract]. Hepatology 1997;26:260a
24. Boker KH, Ringe B, Kruger M, et al. Prostaglandin E plus famciclovir-a now concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994;57:1706-1708
25. Neuhaus P, Manns MP, Atkinson G. Safety and efficacy of famciclovir for the treatment of recurrent hepatitis B in liver transplant recipients [abstract]. Hepatology 1997;26:260a
26. Jaeckel E, Tillmann HL, Kruger M, et al. Prolonged therapy of recurrent hepatitis B infection after liver transplantation with nucleoside analogues [abstract]. J Hepatol 1998;28(suppl):115a
27. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435
28. Aye TT, Bartholomeusz AI, Shaw T, et al. Hepatitis B virus polymerase mutations during famciclovir therapy in patients following liver transplantation [abstract]. Hepatitis 1996;24:285a
29. Aye TT, Bartholomeusz AI, Shaw T, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997;26:1148-1153
30. Tipples GA, Ma MM, Fischer KP, et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-717
31. Bartholomew MM, Jansen RW, Jeffers LH, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1996;348:1212-1215
32. Wolters LMM, Honkoop P, de Man RA, et al. Famciclovir treatment in lamivudine resistant chronic hepatitis B patients [abstract]. J Hepatol 1998;28(Suppl 1):113a
33. Tillmann HL, Trautwein C, Bock T, et al. Response and mutations in patients sequentially treated with lamivudine and famciclovir for recurrent hepatitis B after liver transplantation [abstract]. Hepatology 1997;26:429a
34. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1997;27:628-633
35. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997;26:216-225
36. Nowak MA, Bonhoeffer S, Hill AM, et al. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996;93:4398-4402
37. Xioing X, Flores C, Gibbs C, et al. Lack of cross resistance to PMEA for human hepatitis B DNA polymerases which express lamivudine resistance codons [abstract]. Hepalology 1997; 26:431a